What 1,136 Client Reports Taught Me About Why You’re Still in Pain

By Katie, Founder of Molecular Health Co and the Institute of Integrative Biomedicine

I’ve spent years working inside the intersection of genetics, orthomolecular medicine, and nutrigenomics. My work at Molecular Health Co involves analyzing DNA reports for clients dealing with everything from joint pain and fibromyalgia to migraines, chronic inflammation, and the kind of full-body aching that doctors keep telling people is “normal” or “stress.”

It is not normal. And it is not stress.

After reviewing over 1,100 client reports that included a pain component, eight patterns showed up so consistently that I can no longer call them coincidences. These are physiological patterns written into the genome, playing out in real bodies, producing real symptoms that are being mismanaged every single day.

This is what I found.

Why Genetics and Pain Are More Connected Than You Think

Most conversations about chronic pain stay inside the musculoskeletal system. Something is inflamed, something is structurally compromised, or a nerve is being compressed. The standard of care addresses what can be seen on imaging or felt in the tissue.

But genetics operates several layers upstream of that. Your DNA influences how you process neurotransmitters, how efficiently your immune system resolves inflammation, how well your cells handle oxidative damage, how your hormones metabolize, and how strongly your nervous system registers a pain signal in the first place.

When those upstream processes are running inefficiently because of inherited genetic variants, pain becomes harder to trigger a recovery from. The tissue heals, but the underlying biochemical environment that amplified the pain in the first place stays the same. That’s why so many people with chronic pain feel like nothing fully works. They’re treating the output without addressing the input.

The eight theories below are drawn directly from over a thousand real client reports. Each one represents a pattern I saw repeatedly, across different people, different pain presentations, and different life circumstances. Together, they tell a coherent story about why pain persists and what the body actually needs to resolve it.

COMT Is the Pain Amplifier Nobody Talks About

COMT stands for Catechol-O-Methyltransferase. It’s an enzyme responsible for breaking down catecholamines, which include dopamine, norepinephrine, and epinephrine. It also plays a major role in clearing estrogen metabolites.

The COMT gene variant rs4680, known as V158M, showed up in every single one of my pain-containing client reports. Every one. That figure alone stopped me.

Here’s why it matters for pain. Dopamine is not just a feel-good neurotransmitter. It plays a significant role in pain modulation. The brain uses dopamine in descending pain inhibitory pathways. These are the circuits that tell the nervous system to turn the volume down on a pain signal. When dopamine clearance is slowed by reduced COMT activity, the dopamine available in these inhibitory pathways becomes dysregulated. The result is a lower pain threshold and a reduced ability to naturally dampen pain perception.

People with the COMT V158M variant are often described in the research literature as having higher pain sensitivity. They tend to experience the same stimuli as more painful than those with normal COMT activity. They also tend to have a harder time recovering from pain states because the neurochemical regulation needed for resolution is compromised.

On top of that, slower catecholamine clearance keeps the sympathetic nervous system in a more activated state. This is the fight-or-flight branch of the autonomic nervous system. Chronic sympathetic dominance sustains elevated cortisol and norepinephrine, both of which sustain inflammation. The pain doesn’t just feel worse. It physiologically persists longer.

This variant is extremely common. And it’s almost never discussed in a clinical pain management context. Most people carrying it have no idea it’s influencing every pain experience they have.

Your Histamine Load Is Setting Your Pain Baseline

In 96% of my pain-containing client reports, three things appeared together: elevated histamine burden, COMT variants, and pain. That’s not a coincidence. That’s a physiological loop.

Histamine is widely known as the molecule behind allergic reactions, but its role in pain is far less understood in mainstream medicine. Histamine directly activates nociceptors, which are the sensory nerve endings that detect and transmit pain signals. Higher histamine levels mean a more sensitized pain system. The threshold for what triggers a pain response gets lower. Background discomfort intensifies. Flares feel disproportionate to the trigger.

The connection to COMT is this: both dopamine and histamine share breakdown pathways. COMT is involved in the clearance of catecholamines, and slow COMT activity keeps the sympathetic nervous system elevated, which in turn stimulates mast cells to release more histamine. Meanwhile, the gut, hormonal system, and immune system all have their own contributions to histamine load.

Gut dysbiosis increases histamine-producing bacteria. Slow estrogen clearance via CYP enzyme variants raises circulating estrogen, which stimulates histamine release from mast cells. And histamine, once elevated, stimulates more estrogen production. These two systems drive each other in a bidirectional loop.

The practical result is a person whose baseline histamine level is chronically elevated, whose nervous system is chronically sensitized, and whose pain never fully resolves between episodes because the underlying biochemical environment stays in a pro-pain state.

Clients in this pattern often describe their pain as unpredictable. They’ll have a pain flare that seems to have no clear cause, or they’ll notice pain worsens around their menstrual cycle, after certain foods, or during stress. All of those triggers are histamine drivers. The genetics set the terrain. The exposures pull the trigger.

Migraines Are a Methylation Problem First

Methylation appeared in 99% of my pain reports. When I narrowed the analysis specifically to migraine, MTHFR variants appeared in 98% of those cases.

MTHFR encodes an enzyme that converts folate into its active form, 5-methyltetrahydrofolate. This active folate is the rate-limiting input for the methylation cycle, which governs a remarkable range of downstream physiological processes including homocysteine clearance, neurotransmitter synthesis, DNA repair, gene expression regulation, and nitric oxide metabolism.

Every one of those downstream processes has a direct relationship with migraine physiology.

Homocysteine elevates when methylation is inefficient. Elevated homocysteine promotes vascular inflammation and impairs endothelial function. The blood vessels supplying the brain become more reactive and prone to the vasodilation that underlies the migraine cascade.

Nitric oxide regulation is another piece. Nitric oxide is a potent vasodilator. NOS3 variants, which also appeared frequently in my migraine data, can dysregulate nitric oxide synthesis. Combined with impaired methylation and elevated homocysteine, the vascular environment becomes prone to the kind of instability that precedes a migraine episode.

Then there’s serotonin. The methylation cycle is upstream of serotonin synthesis. Serotonin is the primary neurotransmitter targeted by triptan medications, the most commonly prescribed migraine drugs. But when methylation is compromised, the raw material availability and cofactor status for serotonin production are both impaired. You can take the medication that acts on serotonin receptors, but if the system isn’t producing serotonin efficiently, the intervention has a limited ceiling.

Migraine is often described as a neurological condition with a vascular component. I’d add a third descriptor: it’s a methylation condition with neurological and vascular expression.

Structural Pain Patients Have a Collagen Gene Variant That’s Being Missed

Joint pain appeared in 255 client reports. COL1A1 and COL5A1 gene variants showed up in 172 of those, alongside persistent pain and, frequently, normal or near-normal imaging findings.

This is one of the patterns that strikes me as most clinically significant, because it explains a scenario that frustrates both patients and practitioners: the person with real, consistent, activity-limiting joint pain who is told their imaging is fine.

COL1A1 encodes type I collagen, the primary structural protein in tendons, ligaments, bone matrix, and skin. COL5A1 encodes type V collagen, which regulates the diameter and assembly of collagen fibers. Variants in either gene do not produce visible structural defects on MRI. They produce changes in fiber quality, repair kinetics, and mechanical load tolerance.

Connective tissue with altered collagen structure responds differently to repetitive loading. It sustains micro-damage more readily, heals more slowly, and has a lower threshold for the inflammatory signaling that produces pain. A person with these variants doing the same activities as someone without them will accumulate tissue stress at a faster rate and resolve it more slowly.

They’re not making up the pain. The pain is real, and it has a genetic substrate that standard imaging doesn’t assess.

These clients also frequently have neck pain, spondylosis, and hip pain documented in their reports. All of these are areas of high connective tissue demand. When the raw material quality is compromised at the genetic level and inflammation and oxidative stress are also elevated as separate genetic factors, the joint environment is under compounded strain.

The intervention isn’t just anti-inflammatory. Collagen synthesis requires specific nutritional inputs. Vitamin C is a required cofactor for the hydroxylation of proline and lysine in collagen assembly. Without adequate vitamin C, collagen fibers are structurally weak regardless of how much protein a person consumes. Copper, zinc, and silica also participate in collagen crosslinking and maturation. These are not optional additions for people with COL variants. They’re rate-limiting factors.

Oxidative Stress Appeared in Every Single Pain Report

One hundred percent. Every report in my pain dataset also contained oxidative stress as a contributing factor. This is not subtle. This is foundational.

Oxidative stress occurs when the production of reactive oxygen species outpaces the body’s antioxidant capacity. Free radicals damage cell membranes, mitochondrial DNA, proteins, and lipid structures. In the context of pain, oxidative stress has several specific and significant effects.

First, it directly amplifies inflammatory signaling. NF-κB, the master transcription factor for pro-inflammatory cytokines including IL-6, TNF-alpha, and IL-1β, is activated by oxidative stress. More free radicals mean more inflammatory signaling. More inflammatory signaling means more pain.

Second, oxidative stress impairs tissue repair. Collagen synthesis, mitochondrial function, and cellular membrane integrity all depend on a low-oxidative environment. When that environment is persistently compromised by genetic variants in antioxidant enzymes, recovery from any tissue injury is slowed.

The gene variants most commonly present in my pain reports included SOD2, NQO1, GPX1, and GSTP1. SOD2 encodes the mitochondrial superoxide dismutase enzyme. Variants in rs4880 reduce the efficiency of this enzyme, meaning mitochondria accumulate superoxide radicals more readily. NQO1 and GPX1 variants reduce the efficiency of glutathione recycling and antioxidant defense. GSTP1 affects glutathione conjugation, which is central to detoxification and phase II liver function.

These are not rare variants. They are common, they are inherited, and they create a baseline oxidative burden that most pain treatment protocols completely ignore. When you treat inflammation with an anti-inflammatory and don’t address the upstream oxidative drive, you’re managing a symptom of a symptom.

The nutritional cofactors these antioxidant enzymes require include zinc, selenium, riboflavin, glutathione precursors such as N-acetylcysteine, and vitamin C. Getting these into the system in therapeutic amounts is not a wellness gesture. For people with these variants, it’s a physiological requirement.

The Estrogen-Histamine-Pain Loop in Women

This pattern appeared so consistently in female client reports that it deserves its own dedicated discussion.

CYP1B1 and CYP enzyme variants affect phase I estrogen metabolism. COMT variants affect phase II estrogen clearance. When both are present, estrogen metabolites accumulate. Elevated estrogen, particularly in the follicular phase and the week before menstruation, stimulates mast cells to release histamine. And histamine, as described above, directly sensitizes nociceptors and lowers the pain threshold.

But it goes further. Histamine also stimulates the ovaries to produce more estrogen. These two systems reinforce each other, and the result is a cyclical pattern of pain that intensifies at predictable hormonal points in the month. Pelvic pain, joint pain, headaches, and heightened sensitivity to touch or pressure all tend to worsen in the premenstrual window in people with this genetic constellation.

Endometriosis appeared 25 times in my pain dataset. Painful menstruation was documented in multiple reports. Perimenopausal joint pain, with the specific framing of pain that began or worsened around hormonal transitions, appeared in numerous reports with the COMT and CYP co-variant pattern.

What’s important to understand here is that the pain is not primarily a uterine problem, a hormonal problem, or an inflammatory problem in isolation. It’s a clearance problem. The body is not efficiently processing and eliminating estrogen, so estrogen accumulates in its most biologically active and reactive forms, drives histamine upward, and the histamine sustains a sensitized, lower-threshold pain state.

Supporting phase II liver detoxification with adequate B vitamins for methylation, sulfur amino acids for sulfation and glutathione production, and cruciferous vegetable compounds for glucuronidation creates the biochemical conditions for estrogen to move through the clearance pathway efficiently. This is where nutrigenomics becomes therapeutically specific rather than generally supportive.

The Gut Is Upstream of Inflammatory Pain

Gut and pain appeared together in 82% of my client reports. Gut microbiome and pain appeared together in 50% of them. These numbers are high enough to suggest a structural relationship, not a coincidental one.

The gut-pain connection runs through several distinct mechanisms. The most direct is intestinal permeability. When the gut lining is compromised, bacterial lipopolysaccharide (LPS) crosses into systemic circulation. LPS is a potent activator of TLR4 receptors on immune cells, triggering IL-6 and TNF-alpha production. These are the same cytokines that drive inflammatory pain, fatigue, and central sensitization.

FUT2 variants appeared frequently in my gut-pain reports. FUT2 affects the secretion of blood type antigens into mucosal surfaces including the gut, which in turn influences which bacteria can adhere to and colonize the intestinal lining. FUT2 variants are associated with altered microbiome composition and increased susceptibility to gut dysbiosis.

SLC22A4 variants affecting organic cation transport also appeared, as did ICAM1 variants influencing immune cell adhesion to gut epithelium. Together, these create a genetic picture of a gut environment that is more prone to permeability, more prone to dysbiosis, and more prone to driving systemic immune activation.

The clinical pattern this produces is a person with chronic pain who also has gut symptoms, who often feels worse after eating certain foods, and who notices that inflammatory flares and gut flares tend to happen together. They’re not coincidental. They’re causally linked at the genetic and physiological level.

Histamine-producing bacteria in a dysbiotic gut also add to the systemic histamine burden described earlier. The gut, the immune system, and the pain system are not separate problems requiring separate protocols. They are the same problem expressed in different tissues.

Magnesium Deficiency and Pain Are Nearly Inseparable

Magnesium appeared alongside pain in 95.8% of my client reports. That figure has stayed with me since I first calculated it.

Magnesium is a cofactor in over 300 enzymatic reactions. In the context of pain, its most significant role is in regulating NMDA receptor activity. The NMDA receptor is a glutamate receptor on neurons that, when chronically activated, drives a process called central sensitization. Central sensitization is the mechanism behind fibromyalgia, chronic widespread pain, and the phenomenon where the nervous system becomes amplified in its sensitivity to the point where normal stimuli register as painful.

Magnesium sits in the NMDA receptor channel and blocks it under resting conditions. When magnesium is depleted, this blockade is lost. The receptor becomes more easily activated by glutamate, the nervous system becomes more excitable, and pain signals are amplified and prolonged. This is not a subtle effect. Magnesium deficiency is one of the primary drivers of central sensitization, and central sensitization is one of the primary reasons chronic pain becomes self-sustaining.

Fibromyalgia appeared in 57 client reports. Every single one also contained the COMT variant discussed earlier. Fibromyalgia is increasingly understood as a condition of central sensitization, and the genetic substrates driving that sensitization include COMT variants reducing pain inhibition, magnesium-dependent NMDA regulation being compromised by depletion, and oxidative stress amplifying inflammatory signaling throughout the nervous system.

Magnesium is also required for ATP synthesis, which means every cell in the body depends on it for energy production. Mitochondrial dysfunction, which appeared in 87.6% of my pain reports, worsens when magnesium is inadequate. Nerve conduction, muscle relaxation, sleep quality, and cortisol regulation all depend on magnesium. When it is chronically low, everything downstream becomes less efficient.

Genetic factors also influence magnesium status independently of diet. Variants affecting intestinal absorption and renal retention mean some people lose magnesium more readily and have difficulty maintaining adequate tissue levels even with good dietary intake. This genetic substrate makes supplementation not just helpful but often necessary to reach therapeutic tissue levels.

What I’ve Learned From All of This

These eight patterns, observed across over a thousand real client reports, point to a consistent conclusion. Chronic pain is rarely a single-pathway problem. It is a convergence of genetic inefficiencies across the antioxidant system, the methylation cycle, neurotransmitter metabolism, hormone clearance, connective tissue synthesis, gut barrier integrity, and micronutrient-dependent enzyme function.

When any one of these pathways is compromised, pain becomes easier to trigger and harder to resolve. When several are compromised simultaneously, which is what I see in the majority of my pain clients, the result is a body living in a state of chronic physiological vulnerability where pain becomes the default response to what should be manageable physiological stressors.

The reason standard treatments often fail to provide lasting relief is that they target the output: the inflammation, the pain signal, the tight muscle. They don’t address the genetic and nutritional inputs that are keeping the system in a pain-prone state. Anti-inflammatories suppress COX enzymes but don’t address COMT-driven central sensitization. Magnesium supplementation helps, but if the dose and form aren’t matched to the individual’s absorption genetics, the benefit is limited. A low-histamine diet helps, but if the underlying mast cell activation is being driven by an estrogen clearance problem that isn’t being addressed, the dietary restriction becomes a permanent management strategy rather than a path toward resolution.

Personalization is not a wellness marketing term. In the context of pain genetics, it is a physiological necessity. The interventions that matter most depend entirely on which variants an individual carries.

What Can Actually Help

Based on what I’ve seen across this dataset, meaningful pain support requires knowing which pathways are compromised before choosing interventions. The most important starting point is understanding your own genetic landscape.

Molecular Health Co DNA Reports are designed to do exactly this. The Genetic Report analyzes your confirmed SNP list across the pathways most relevant to pain, including COMT, MTHFR, SOD2, COL1A1, COL5A1, IL6, TNF, NQO1, GPX1, VDR, FADS1, FUT2, and many more. The report doesn’t just list your variants. It explains what each one means for your physiology, how the variants interact with each other, and what the specific nutritional and lifestyle priorities are given your unique genetic profile.

The **Sensitivity Report** maps your genetic tendency toward histamine intolerance, mast cell reactivity, and food sensitivities, which, as the data above shows, are present in the vast majority of chronic pain cases.

The **Hormone Report** addresses the estrogen-histamine-pain loop directly, identifying how efficiently you clear estrogen through each phase of detoxification, where the bottlenecks are, and what nutrient and lifestyle support is most relevant to your clearance profile.

If pain is something you’ve been managing rather than resolving, that distinction is worth examining. Management keeps you functional inside the problem. Resolution requires understanding why the problem exists in the first place.

Your DNA holds a significant portion of that answer. The reports I’ve built are designed to make that information usable: clear, physiology-first, and specific to how your body actually works.

Explore the Molecular Health Co DNA Kit and Reports.

*Katie is the founder of Molecular Health Co and the Institute of Integrative Biomedicine. Her work focuses on the intersection of genetics, orthomolecular medicine, and nutrigenomics, with a particular interest in how inherited gene variants shape chronic health conditions including pain, hormonal imbalance, mental health, and immune dysregulation.